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A 59-year-old man was admitted to a dental clinic complaining of toothache and high fever
in May 2007. Laboratory studies demonstrated pancytopenia and severe inﬂammatory
ﬁndings. Therefore, he was admitted to our hospital. The patient was diagnosed with
acute myeloid leukemia with multilineage dysplasia and severe pulpitis. After treatment
with antibiotics and lenograstim was initiated, acute respiratory distress syndrome (ARDS)
was induced. This is, to our knowledge, the ﬁrst case of lenograstim-induced ARDS,
resistant to corticosteroids alone, which was successfully treated with both corticosteroids
and cyclosporin.
& 2008 Elsevier Ltd. All rights reserved.Case report
We diagnosed a 59-year-old man, who presented with
toothache to a dental clinic, with pulpitis, and prescribedElsevier Ltd. All rights reserved.
683 1221;
med.ac.jp (S. Nakayama).antimicrobial treatment. He was admitted to our hospital
when the clinical symptoms of fever and toothache persisted
for two days.
On admission, the patient’s body temperature was
101.48 1F; pulse rate, 82 beats per minute (bpm); respira-
tion rate, 18 bpm; and blood pressure, 130/72mmHg.
Arterial oxygen saturation by pulse oximetry (SpO2)
was 98% on room air. Physical examination revealed no ly-
mphadenopathy or hepatosplenomegaly. Chest radiography
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Figure 1 (A) Chest radiograph on day 9 after admission.
Diffusely distributed patchy alveolar densities over both lungs,
ﬁndings consistent with the diagnosis of adult respiratory
distress syndrome. (B) Chest radiograph on day 41 following
admission, showing normal appearance of lungs after therapy
with methylprednisolone and cyclosporin.
Successful therapy with high-dose steroids 189ﬁndings were normal. Blood examination ﬁndings were as
follows: white blood cell (WBC) count, 0.73 109 l1
(5% blast cells, 16.5% neutrophils, and 75.1% lymphocytes);
red blood cell (RBC) count, 144 1010 l1; hemoglobin,
60 g l1; platelets, 6.0 109 l1; and C-reactive protein
(CRP), 28.17mgdl1. Bone marrow biopsy demonstrated
hypercellular marrow, and marrow aspirate showed 35.6%
inﬁltration of abnormal cells with irregular conspicuous
nuclei and ﬁne nuclear chromatin. Furthermore, the smears
showed pseudo Pelger–Huet anomaly, micromegakaryo-
cytes, and dyserythropoiesis. Dysplasia was present in
Z50% of the three cell lineages. Cytochemical studies
demonstrated that the majority of blast cells were positive
for myeloperoxidase (MPO). Flow cytometric immunophe-
notyping of cell surface markers with CD45 gating revealed
that most blast cells expressed CD13, CD15, CD33, CD34,
CD36, and HLA-DR, but not CD3, CD4, CD7, and CD20.
Karyotypic analysis with Giemsa-banding of blast cells
demonstrated 50, XY, 5del (11) (p?), 17, 18, 20, +rl,
+rl2, +mar1, +mar2 2, +mar3, +mar4, +mar5[11], 46,
XY[1]. These ﬁndings led to the diagnosis of acute myeloid
leukemia (AML) with multilineage dysplasia as per the World
Health Organization classiﬁcation criteria.1
Intravenous administration of meropenem (1.5 g) and
teicoplanin (400mg) for severe pulpitis was initiated. When
the clinical signs did not improve on day 4 of hospital stay,
subcutaneous lenograstim administration (250 mg day1) was
initiated for severe infection. On day 9, dry cough and
dyspnea suddenly developed and the blood gas levels
deteriorated. Arterial blood gas testing on 4 lmin1 ﬂow of
supplemental oxygen via face mask showed: pH, 7.503;
partial pressure of arterial oxygen (PaO2), 71.5mmHg; and
partial pressure of arterial carbon dioxide (PaCO2),
29.6mmHg. Echocardiography demonstrated normal cardiac
function. PaO2/fraction of inspired oxygen (FiO2) level was
198. Laboratory ﬁndings were consistent with the diagnosis
of ARDS according to the report by the American–European
Consensus Conference on ARDS.2 Emergent examination
demonstrated elevated WBC count and CRP levels:
2.17 109 l1 (blast cells 1.0%, neutrophils 36.8%, and
lymphocytes 45.5%) and 22.35mg dl1, respectively. Results
were negative for total antinuclear antibody, anticardiolipin
antibody, anticardiolipin b2-glycoprotein I antibody, protei-
nase 3-antineutrophil cytoplasmic autoantibody (PR3-ANCA),
MPO-ANCA, and antiglomerular basement membrane anti-
body. Chest radiograph revealed marked inﬁltrative shadows
in bilateral lung ﬁelds (Figure 1A). Bronchoalveolar lavage
(BAL) samples obtained from the right middle lobe during
bronchoscopy appeared to be edematous, and bled easily.
Laboratory tests, including microbiological and cytological
analyses, performed on these samples were negative for
infectious agents, particularly for viruses, pneumocystis
carinii, cytomegalovirus, aspergillus, and cryptococcocus.
The BAL cytogram demonstrated increased numbers of
polymorphonuclear leukocytes. There was no evidence
of pulmonary inﬁltration by blast cells. Results for sputum,
blood, and BAL samples were negative for bacterial
cultures. Since the onset of ARDS was associated with a
rapid increase in the WBC count after administration
of lenograstim, and other causes of ARDS were eliminated,
the clinical course and ﬁndings led to the diagnosis of
lenograstim-induced ARDS. Lenograstim administration washence terminated, and methylprednisolone (500mgday1)
was administered intravenously for three days. On day 11,
improvement of inﬁltrative shadows was seen on chest
radiographs and blood gas levels were apparent at SpO2 98%
on 2 lmin1 oxygen via facemask. On reducing the dose of
prednisolone to 250mg on day 13, dyspnea reappeared,
which was controlled by increasing the methylprednisolone
to 1000mgday1 for three days. On reducing the dose of
prednisolone to 500mg on day 16, dyspnea reappeared on
day 18. Chest radiograph showed recurrence of moderate
interstitial inﬁltrates. Cyclosporin (CsA) (150mg day1) was
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Figure 2 Clinical course. DRPM: deropenem, MINO: minocycline, TEIC: teicoplanin, LVFX: levoﬂoxacin, MEPM: meropenem, CsA:
cyclosporin A, mPSL: methylprednisolone, PSL: prednisolone, ARDS: acute respiratory distress syndrome.
S. Nakayama et al.190initiated and methylprednisolone (500mgday1) was con-
tinued. We attempted to maintain CsA blood trough levels
within 200–250mgml1. Within ﬁve days of initiating CsA
therapy, dyspnea improved. Methylprednisolone was de-
creased to 250mgday1 on day 21, and to 125mgday1 on
day 26. On day 29, it was discontinued and 60mgday1 of
prednisolone was started. As pulmonary symptoms, includ-
ing dyspnea, disappeared and the patient’s general condi-
tion improved, prednisolone was tapered day 33 onwards.
On day 41, chest radiograph had normalized (Figure 1B) and
blood gas levels increased to within normal limits at SpO2
98% on room air. Laboratory examination showed improved
values: WBC, 1.77 109 l1 (blast cells 1%, neutrophils 2.5%,
and lymphocytes 75%) and CRP, 0.05mgdl1. Prednisolone
was discontinued on day 40. As the patient’s general
condition was good, CsA dose was tapered day 60 onwards.
No further worsening of the clinical picture occurred
(Figure 2).Discussion
ARDS is a complex disorder characterized by a neutrophilic
inﬂammatory response associated with increased pulmonary
vascular permeability. The recent European–American Con-
sensus Conference on ARDS deﬁnes it as a condition
involving: (1) impaired oxygenation (PaO2/FiO2 that is
r200 regardless of the level of positive end-expiratory
pressure provided for respiratory support), (2) detection
of bilateral pulmonary inﬁltrates on frontal chest radio-
graph, (3) pulmonary artery occlusion (wedge) pressure
r18mmHg, and (4) no clinical evidence of elevated left
atrial pressure based on radiographic and other clinical
data.2
Pathogenesis of ARDS includes inﬂammation character-
ized by neutrophil accumulation in the lungs during early
stages, and lymphocyte-induced lung ﬁbrosis during late
stages. Neutrophils adhere to the injured capillary endothe-lium and migrate through the interstitum into the air space,
which is ﬁlled with protein-rich edema ﬂuid. In the air
space, alveolar macrophages secreting cytokines, interleu-
kin (IL)-1, IL-6, IL-8, IL-10, and tumor necrosis factor-a act
locally to stimulate chemotaxis and activate neutrophils.
Neutrophils play an important role in the development
of ischemia/reperfusion injury. Activated neutrophils can
cause tissue injury by releasing cytotoxic oxygen free
radicals or neutrophil elastase.3 Neutrophil elastase acts
as an abnormal stimulus to IL-8 production in bronchial
epithelial cells. Thus, neutrophil elastase plays a central
role in the inﬂammatory cycle: stimulation of IL-8 release,
further neutrophil accumulation, and further neutrophil
elastase release.4
Commonly associated clinical disorders can be divided
into those associated with direct injury to the lung and those
that cause indirect lung injury in the setting of a systemic
process.3 Granulocyte colony-stimulating factor (G-CSF)
is one of the most important regulators mediating the
development of ARDS.5,6 G-CSF enhances cytokine produc-
tion and activates the oxidative burst within circulating or
resident alveolar neutrophils and macrophages.7 Previous
studies indicate that G-CSF administration enhances super-
oxide release in neutrophils in patients with malignant
lymphomas.8 The incidence of ARDS due to pulmonary
infection was higher in the G-CSF group than in controls.
These ﬁndings suggest that G-CSF promotes the develop-
ment of ARDS due to pulmonary infection.9
CsA and corticosteroids are immunosuppressive drugs.
They have found widespread application in the treatment of
transplant rejection, aplastic anemia, nephritic syndrome,
etc. The potent anti-inﬂammatory and immunomodulatory
actions of corticosteroids are due to the inhibition of
activity of transcription factors such as activator protein
(AP)-1 and nuclear factor kb (NF-kb), which activate
proinﬂammatory genes.10 CsA binds to its cognate intracel-
lular receptor immunophilins, cyclophilin (CyP)-binding
protein. The binding of CsA–CyP complex to calcineurin
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Table 1 Summary of a randomized controlled trial of the various drugs for ARDS.
Drug Drug/
placebo
Mortality or ventilation-free
(drug/placebo)
Mortality (%)
(drug/placebo)
Ventilation-free (days)
(drug/placebo)
Reference
Methylprednisolone 50/49 Mortality 60/63 10
Methylprednisolone 50/38 Mortality 52/21 11
Sivelestat 241/246 Ventilation free 11.4/11.9 12
Mortality 26/26.6
Prostaglandin E1 177/171 Ventilation free 16.9/19.6 13
Mortality 32/29
Ketoconazole 117/117 Ventilation free 9/10 14
Mortality 34.1/35.2
Lisofylline 116/119 Ventilation free 9/11 15
Mortality 31.9/24.7
Ibuprofen 224/231 Mortality 37/40 16
N-acetylcysteine 14/15 Mortality 40/35 17
Nitric oxide 192/193 Ventilation free 10.7/11.6 18
Mortality 23/20
Protein C 224/224 Ventilation free 0/1 19
Successful therapy with high-dose steroids 191inhibits its catalytic activity. CsA exerts control via a
calcineurin-dependent pathway.11 Inhibition of calcineurin
by CsA blocks certain signals important for cytokine gene
expression. CsA speciﬁcally inhibits the appearance of DNA-
binding activity of nuclear factor of activated T cells, AP-3,
and to a lesser extent NF-kb, nuclear proteins that appear to
be important in the transcriptional activation of genes for
interleukin-2 and its receptor, as well as several other
lymphokines. The drug is thought to act via T-helper cells by
inhibiting mRNA transcription of IL-2, IL-3, IL-4, and gamma
interferon.12 One study described the inhibitory effect of
CsA on G-CSF production by endothelial cells at 500 ngml1
concentration. Researchers veriﬁed a minor downregulating
effect of CsA on G-CSF secretion by endothelial cells.13
Moreover, CsA may play a role in suppressing G-CSF in
the cytokine network. Furthermore, CsA causes recovery
of intracellular corticosteroids in lymphocytes by competi-
tively binding to p-glycoprotein (P-gp), which expels
intracellular drugs, thus reducing the excretion of dexa-
methasone in IL-2-activated lymphocytes at a lower con-
centration than the clinical trough levels used for inhibiting
calcineurin. Downregulation of P-gp by intensive CsA
therapy may be important for overcoming corticosteroid
resistance.14 Therefore, a combination regimen of CsA and
corticosteroids may be more effective than CsA or corticos-
teroids alone, because their mechanisms of action are
different. Several clinical studies have reported its effec-
tiveness in steroid-resistant dermatomyositis/polymyosi-
tis,15,16 rheumatoid arthritis,17 and interstitial pneumonitis
associated with Sjogren’s syndrome.18
Corticosteroids,19,20 neutrophil elastase inhibitors,21 lipo-
somal prostaglandin E1,22 ketoconazole,23 lisofylline,24
ibuprofen,25 N-acetylcysteine,26 inhaled nitric oxide,27 and
recombinant surfactant28 are the reported therapies for
ARDS. However, randomized trials of pharmacological
therapies have not reduced mortality from ARDS (Table 1).
No speciﬁc pharmacological therapies have yet proven to be
efﬁcacious. Although no study has determined whether
corticosteroids alter the course of established G-CSF-induced ARDS, a condition for which corticosteroids are
commonly used. However, there are some unsuccessful
cases despite corticosteroid treatment. Corticosteroid ther-
apy is not sufﬁcient in treating ARDS related to G-CSF
administration.29–33 This is, to our knowledge, the ﬁrst case
of ARDS during lenograstim-induced neutropenia recovery,
resistant to corticosteroids alone, successfully treated with
both corticosteroids and CsA in AML with multilineage
dysplasia. This case illustrates the potential use of CsA in
patients with G-CSF-induced ARDS resistant to corticoster-
oid therapy.Conﬂict of interest statement
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